192 related articles for article (PubMed ID: 37377889)
1. Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics.
Wang S; Xia Z; You J; Gu X; Meng F; Chen P; Tang W; Bao H; Zhang J; Wu X; Shao Y; Wang J; Zuo X; Xu L; Yin R
Cancer Res Commun; 2023 May; 3(5):933-942. PubMed ID: 37377889
[TBL] [Abstract][Full Text] [Related]
2. Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II-IIIA NSCLC patients.
Vessies DCL; Schuurbiers MMF; van der Noort V; Schouten I; Linders TC; Lanfermeijer M; Ramkisoensing KL; Hartemink KJ; Monkhorst K; van den Heuvel MM; van den Broek D
Mol Oncol; 2022 Jul; 16(14):2719-2732. PubMed ID: 35674097
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer.
Wang S; Li M; Zhang J; Xing P; Wu M; Meng F; Jiang F; Wang J; Bao H; Huang J; Ren B; Yu M; Qiu N; Li H; Yuan F; Zhang Z; Jia H; Lu X; Zhang S; Wang X; Xu Y; Xia W; Liu T; Xu W; Xu X; Sun M; Wu X; Shao Y; Wang Q; Dai J; Qiu M; Wang J; Zhang Q; Xu L; Shen H; Yin R
J Hematol Oncol; 2022 Oct; 15(1):137. PubMed ID: 36183093
[TBL] [Abstract][Full Text] [Related]
4. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
Xia L; Mei J; Kang R; Deng S; Chen Y; Yang Y; Feng G; Deng Y; Gan F; Lin Y; Pu Q; Ma L; Lin F; Yuan Y; Hu Y; Guo C; Liao H; Liu C; Zhu Y; Wang W; Liu Z; Xu Y; Li K; Li C; Li Q; He J; Chen W; Zhang X; Kou Y; Wang Y; Wu Z; Che G; Chen L; Liu L
Clin Cancer Res; 2022 Aug; 28(15):3308-3317. PubMed ID: 34844976
[TBL] [Abstract][Full Text] [Related]
5. Ultra-short cell-free DNA fragments enhance cancer early detection in a multi-analyte blood test combining mutation, protein and fragmentomics.
Wang F; Li X; Li M; Liu W; Lu L; Li Y; Chen X; Yang S; Liu T; Cheng W; Weng L; Wang H; Lu D; Yao Q; Wang Y; Wu J; Wittkop T; Faham M; Zhou H; Hu H; Jin H; Hu Z; Ma D; Cheng X
Clin Chem Lab Med; 2024 Jan; 62(1):168-177. PubMed ID: 37678194
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA-minimal residual disease: An up-and-coming nova in resectable non-small-cell lung cancer.
Li FQ; Cui JW
Crit Rev Oncol Hematol; 2022 Nov; 179():103800. PubMed ID: 36031171
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor DNA minimal residual disease in clinical practice of non-small cell lung cancer.
Xia J; Zhang J; Xiong Y; Zhao J; Zhou Y; Jiang T; Zhu J
Expert Rev Mol Diagn; 2023; 23(10):913-924. PubMed ID: 37702546
[TBL] [Abstract][Full Text] [Related]
8. Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.
Waldeck S; Mitschke J; Wiesemann S; Rassner M; Andrieux G; Deuter M; Mutter J; Lüchtenborg AM; Kottmann D; Titze L; Zeisel C; Jolic M; Philipp U; Lassmann S; Bronsert P; Greil C; Rawluk J; Becker H; Isbell L; Müller A; Doostkam S; Passlick B; Börries M; Duyster J; Wehrle J; Scherer F; von Bubnoff N
Mol Oncol; 2022 Jan; 16(2):527-537. PubMed ID: 34653314
[TBL] [Abstract][Full Text] [Related]
9. Multidimensional Cell-Free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer.
Wang S; Meng F; Li M; Bao H; Chen X; Zhu M; Liu R; Xu X; Yang S; Wu X; Shao Y; Xu L; Yin R
Am J Respir Crit Care Med; 2023 May; 207(9):1203-1213. PubMed ID: 36346614
[No Abstract] [Full Text] [Related]
10. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
11. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
Li N; Wang BX; Li J; Shao Y; Li MT; Li JJ; Kuang PP; Liu Z; Sun TY; Wu HQ; Ou W; Wang SY
Cancer; 2022 Feb; 128(4):708-718. PubMed ID: 35076939
[TBL] [Abstract][Full Text] [Related]
12. Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non-small cell lung cancer patients.
Li H; Ma ZL; Li B; Pan YJ; Xiang JQ; Zhang YW; Sun YH; Hou T; Lizaso A; Chen Y; Li X; Hu H
Cancer Med; 2021 Dec; 10(23):8377-8386. PubMed ID: 34664796
[TBL] [Abstract][Full Text] [Related]
13. Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent.
Pellini B; Chaudhuri AA
J Clin Oncol; 2022 Feb; 40(6):567-575. PubMed ID: 34985936
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.
Zhong R; Gao R; Fu W; Li C; Huo Z; Gao Y; Lu Y; Li F; Ge F; Tu H; You Z; He J; Liang W
BMC Med; 2023 May; 21(1):180. PubMed ID: 37173789
[TBL] [Abstract][Full Text] [Related]
15. Prognostic potential of circulating tumor DNA detection at different time periods in resectable non-small cell lung cancer: Evidence from a meta-analysis.
Wang B; Pei J; Wang S; Cheng K; Yu J; Liu J
Crit Rev Oncol Hematol; 2022 Sep; 177():103771. PubMed ID: 35905822
[TBL] [Abstract][Full Text] [Related]
16. Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling.
Guo W; Chen X; Liu R; Liang N; Ma Q; Bao H; Xu X; Wu X; Yang S; Shao Y; Tan F; Xue Q; Gao S; He J
EBioMedicine; 2022 Jul; 81():104131. PubMed ID: 35780566
[TBL] [Abstract][Full Text] [Related]
17. PEAC: An Ultrasensitive and Cost-Effective MRD Detection System in Non-small Cell Lung Cancer Using Plasma Specimen.
Xu J; Pu Y; Lin R; Xiao S; Fu Y; Wang T
Front Med (Lausanne); 2022; 9():822200. PubMed ID: 35308511
[TBL] [Abstract][Full Text] [Related]
18. Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection.
Bao H; Wang Z; Ma X; Guo W; Zhang X; Tang W; Chen X; Wang X; Chen Y; Mo S; Liang N; Ma Q; Wu S; Xu X; Chang S; Wei Y; Zhang X; Bao H; Liu R; Yang S; Jiang Y; Wu X; Li Y; Zhang L; Tan F; Xue Q; Liu F; Cai S; Gao S; Peng J; Zhou J; Shao Y
Mol Cancer; 2022 Jun; 21(1):129. PubMed ID: 35690859
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer.
Zhang JT; Liu SY; Gao W; Liu SM; Yan HH; Ji L; Chen Y; Gong Y; Lu HL; Lin JT; Yin K; Jiang BY; Nie Q; Liao RQ; Dong S; Guan Y; Dai P; Zhang XC; Yang JJ; Tu HY; Xia X; Yi X; Zhou Q; Zhong WZ; Yang XN; Wu YL
Cancer Discov; 2022 Jul; 12(7):1690-1701. PubMed ID: 35543554
[TBL] [Abstract][Full Text] [Related]
20. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer.
Parsons HA; Rhoades J; Reed SC; Gydush G; Ram P; Exman P; Xiong K; Lo CC; Li T; Fleharty M; Kirkner GJ; Rotem D; Cohen O; Yu F; Fitarelli-Kiehl M; Leong KW; Hughes ME; Rosenberg SM; Collins LC; Miller KD; Blumenstiel B; Trippa L; Cibulskis C; Neuberg DS; DeFelice M; Freeman SS; Lennon NJ; Wagle N; Ha G; Stover DG; Choudhury AD; Getz G; Winer EP; Meyerson M; Lin NU; Krop I; Love JC; Makrigiorgos GM; Partridge AH; Mayer EL; Golub TR; Adalsteinsson VA
Clin Cancer Res; 2020 Jun; 26(11):2556-2564. PubMed ID: 32170028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]